
Denis Y Logunov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9113368/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New Therapy for Spinal Cord Injury: Autologous Genetically-Enriched Leucoconcentrate Integrated with Epidural Electrical Stimulation. Cells, 2022, 11, 144.	4.1	8
2	Boosting of the SARS-CoV-2–Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Journal of Immunology, 2022, 208, 1139-1145.	0.8	10
3	Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy. EClinicalMedicine, 2022, 46, 101360.	7.1	17
4	COVID-19 vaccination and HIV-1 acquisition. Lancet, The, 2022, 399, e34-e35.	13.7	3
5	Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines, 2022, 10, 817.	4.4	16
6	Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines, 2022, 10, 938.	4.4	15
7	Evaluation of Direct and Cell-Mediated Lactoferrin Gene Therapy for the Maxillofacial Area Abscesses in Rats. Pharmaceutics, 2021, 13, 58.	4.5	5
8	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, The, 2021, 397, 671-681.	13.7	1,339
9	Impact of pathogen reduction methods on immunological properties of the COVIDâ€19 convalescent plasma. Vox Sanguinis, 2021, 116, 665-672.	1.5	13
10	Human TRIM14 protects transgenic mice from influenza A viral infection without activation of other innate immunity pathways. Genes and Immunity, 2021, 22, 56-63.	4.1	2
11	Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply. Lancet, The, 2021, 397, 1883-1884.	13.7	17
12	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq0 0 0	rgBT_/Over	rloçk 10 Tf 50
13	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, The, 2020, 396, 887-897.	13.7	822
14	Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors' reply. Lancet, The, 2020, 396, e54-e55.	13.7	25

15	Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice. Vaccines, 2020, 8, 519.	4.4	11
16	<p>NOD1/2 and the C-Type Lectin Receptors Dectin-1 and Mincle Synergistically Enhance Proinflammatory Reactions Both In Vitro and In Vivo</p> . Journal of Inflammation Research, 2020, Volume 13, 357-368.	3.5	4
17	The Preparation of Convencent Plasma and Recruiting of Donors during the COVID-19 Pandemic. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 446-454.	0.6	0
18	Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice. Toxins, 2019, 11, 464.	3.4	38

DENIS Y LOGUNOV

#	Article	IF	CITATIONS
19	Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection. Antiviral Research, 2019, 172, 104617.	4.1	5
20	Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa. Journal of Immunology Research, 2018, 2018, 1-13.	2.2	10
21	The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector. BMC Immunology, 2018, 19, 26.	2.2	7
22	Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS ONE, 2018, 13, e0191574.	2.5	23
23	Post–spinal cord injury astrocyte-mediated functional recovery in rats after intraspinal injection of the recombinant adenoviral vectors Ad5-VECF and Ad5-ANG. Journal of Neurosurgery: Spine, 2017, 27, 105-115.	1.7	16
24	Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2758-E2765.	7.1	66
25	Spinal Cord Molecular and Cellular Changes Induced by Adenoviral Vector- and Cell-Mediated Triple Gene Therapy after Severe Contusion. Frontiers in Pharmacology, 2017, 8, 813.	3.5	23
26	Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against <i>Chlamydia muridarum</i> Intravaginal Infection. BioMed Research International, 2017, 2017, 1-14.	1.9	25
27	Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses. PLoS ONE, 2016, 11, e0155650.	2.5	32
28	Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis. PLoS ONE, 2016, 11, e0150958.	2.5	13
29	Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer. Journal of Translational Medicine, 2014, 12, 322.	4.4	30
30	Sulfatides autoreactivity in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 102-103.	2.3	0
31	Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection. Infection and Immunity, 2013, 81, 3855-3864.	2.2	37
32	Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1857-66.	7.1	112
33	Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Research, 2013, 97, 245-254.	4.1	35
34	Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Research, 2013, 97, 318-328.	4.1	35
35	Topical Bacterial Lipopolysaccharide Application Affects Inflammatory Response and Promotes Wound Healing. Journal of Interferon and Cytokine Research, 2013, 33, 514-522.	1.2	29
36	Development of adenoviral vector-based mucosal vaccine against influenza. Journal of Molecular Medicine, 2011, 89, 331-341.	3.9	35

#	Article	IF	CITATIONS
37	Production of recombinant human lactoferrin in the allantoic fluid of embryonated chicken eggs and its characteristics. Protein Expression and Purification, 2009, 65, 100-107.	1.3	14
38	Identification of HI-Like Loop in CELO Adenovirus Fiber for Incorporation of Receptor Binding Motifs. Journal of Virology, 2007, 81, 9641-9652.	3.4	12